Friendable Inc (OTCMKTS:FDBL) is trying to make a comeback in the market after a recent pullback. Fuelling the upside momentum is a 86.51% decline in short interest which underlines the fact that investors are starting to become bullish on the stock, given the recent wave of positive news. Since June, the stock has risen by 6% having outperformed the S&P 500 BY 0.70%.

In-app Improvements

Download numbers of the social networking app is on the rise further helping affirm Friendable prospects on the street as the same is expected to drive revenues higher going forward. The social networking app has already reiterated plans to make enhancements that are intended to help attract more users as focus shifts to ensuring people spend more time on the network.

Friendable says it is in the process of increasing the speed and capacity of its server code as one of the ways of ensuring faster response times on the app. The same is also expected to help bolster the server capacity especially in handling a number of simultaneous users. Initiated changes have already resulted in 2X to 3X speed increase, with the same expected to improve even further with the upcoming changes.

The company is also exploring ways of enhancing the overall performance in cross-app usage, especially between Android and iOS. Improvements on Android Push and in-app notification are also on the ways part of an effort that seeks to improve user’s experience.

Boosting Download Numbers

All these in-app improvements are intended to increase user interactions on the app. However, the long-term play is using the user interactions to offer advertising opportunities among other sponsorship opportunities. Last month, the company made some strides on this front having appeared in Jennifer Lopez’s latest music video “Ain’t Your Mama”

The company is already reaping dividends from the collaborations, download numbers having soared. Friendable Inc (OTCMKTS:FDBL) expects the user growth rate to continue increasing going forward, from the current 20,000 per month new additions.

OXIS International, Inc. (OTCMKTS:OXIS) Sentiments On The Street Turn Sour

OXIS International, Inc. (OTCMKTS:OXIS) continues to be battered in the market even as it continues to affirm its credential on the development of breakthrough therapies targeting various types of cancer. Its lead candidate drug OXS-1550 continues to show promise in the treatment of Non-Hodgkins Lymphoma.

Preclinical trials have already shown that the drug has the potential to target all cancer cells while leaving all healthy cells untouched. The stock has continued to trade lower in the market in recent trading sessions even on the drug showing fewer side effects when compared to other chemotherapies and cancer treatments.

OXIS International, Inc. (OTCMKTS:OXIS) sentiment on the street has mostly been affected by the fact that it is little known in the market. Given its robust pipeline of drugs still in development, the stock could trade higher on its current clinical trials turning out positive. Other drugs it is working on, include OXS-4235 for the treatment of Multiple Myeloma and OXS-2175 for the treatment of breast cancer.